26039-74-7

Basic information

• Product Name: diethyl (3-chloro-4-nitrophenyl)methylmalonate
• Synonyms: diethyl (3-chloro-4-nitrophenyl)methylmalonate;(3-Chloro-4-nitrophenyl)methylpropanedioic acid diethyl ester
• CAS NO: 26039-74-7
• Molecular Formula: C₁₄H₁₆ClNO₆
• Molecular Weight: 329.73294
• EINECS: 247-424-4
• Mol File: 26039-74-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 430.5°Cat760mmHg
• Flash Point: 214.2°C
• Appearance: /
• Density: 1.306g/cm³
• Vapor Pressure: 1.29E-07mmHg at 25°C
• Refractive Index: 1.534
• CAS DataBase Reference: diethyl (3-chloro-4-nitrophenyl)methylmalonate(CAS DataBase Reference)
• NIST Chemistry Reference: diethyl (3-chloro-4-nitrophenyl)methylmalonate(26039-74-7)
• EPA Substance Registry System: diethyl (3-chloro-4-nitrophenyl)methylmalonate(26039-74-7)

Safety Data

• Hazardous Substances Data: 26039-74-7(Hazardous Substances Data)

Usage

General Description

Diethyl (3-chloro-4-nitrophenyl)methylmalonate is a chemical compound synthesized by the reaction of p-chloronitrobenzene and diethyl malonate. It is commonly used as a building block in organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. diethyl (3-chloro-4-nitrophenyl)methylmalonate is known for its strong electron-withdrawing properties due to the presence of the nitro group, and it is often used as a precursor in the synthesis of various functionalized organic molecules. Additionally, it has been studied for its potential use in the development of new materials and as a tool in chemical biology research. However, it is important to handle this chemical with caution, as it may pose health and environmental risks.

InChI:InChI=1/C14H16ClNO6/c1-3-21-13(17)10(14(18)22-4-2)7-9-5-6-12(16(19)20)11(15)8-9/h5-6,8,10H,3-4,7H2,1-2H3

Upstream product

• 611-06-3 2,4-dichloronitrobenzene 
• 609-08-5 Diethyl methylmalonate 
• 2106-50-5 2-chloro-4-fluoro-1-nitrobenzene 

Downstream Products

• 58810-01-8 Diethyl 2-methyl-2-(3-methylthio-4-nitrophenyl)malonate 
• 25814-36-2 diethyl (4-amino-3-chlorophenyl)methylmalonate 
• 53455-85-9 (±)-2-(3-chloro-4-nitrophenyl)propanoic acid 
• 67333-29-3 (±)-methyl 2-(4-amino-3-chlorophenyl)propanoate 
• 24646-28-4 (±)-methyl 2-(3-chloro-4-nitrophenyl)propanoate 
• 83528-38-5 2-[3-chloro-4-(2'-pyridylamino)phenyl]propionic acid 
• 83528-20-5 2-[3-Chloro-4-(pyridin-2-ylamino)-phenyl]-propionic acid methyl ester 
• 132483-33-1 2-<3-Chloro-4-(thiazol-2-yl)phenyl>propionic Acid 
• 132483-58-0 2-<3-Methylthio-4-(thiazol-2-yl)phenyl>propionic Acid 
• 138568-78-2 2-[3-Chloro-4-(4-methyl-thiazol-2-yl)-phenyl]-propionic acid 
• 138568-82-8 2-[3-Chloro-4-(5-methyl-thiazol-2-yl)-phenyl]-propionic acid 
• 138568-83-9 2-[3-Chloro-4-(5-ethyl-thiazol-2-yl)-phenyl]-propionic acid 
• 138568-79-3 2-[3-Chloro-4-(4-ethyl-thiazol-2-yl)-phenyl]-propionic acid 
• 138568-76-0 2-[4-(4,5-Dimethyl-thiazol-2-yl)-3-fluoro-phenyl]-propionic acid 

Relevant articles and documents

Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of β-amyloid1-42 secretion

Flurbiprofen, a nonsteroidal antiinflammatory drug (NSAID), has been recently described to selectively inhibit β-amyloid1-42 (Aβ42) secretion, the most toxic component of the senile plaques present in the brain of Alzheimer patients. The use of this NSAID in Alzheimer's disease (AD) is hampered by a significant gastrointestinal toxicity associated with cyclooxygenase (COX) inhibition. New flurbiprofen analogues were synthesized, with the aim of increasing Aβ42 inhibitory potency while removing anti-COX activity. In vitro ADME developability parameters were taken into account in order to identify optimized compounds at an early stage of the project. Appropriate substitution patterns at the alpha position of flurbiprofen allowed for the complete removal of anti-COX activity, while modifications at the terminal phenyl ring resulted in increased inhibitory potency on Aβ42 secretion. In rats, some of the compounds appeared to be well absorbed after oral administration and to penetrate into the central nervous system. Studies in a transgenic mice model of AD showed that selected compounds significantly decreased plasma Aβ42 concentrations. These new flurbiprofen analogues represent potential drug candidates to be developed for the treatment of AD.

Nonsteroidal antiinflammatory agents. 2. [(Heteroarylamino)phenyl]alkanoic acids

A series of [(heteroarylamino)phenyl]alkanoic acids pyridine, quinoline, or pyrimidine as the heteroaryl moiety was prepared as potential antiinflammatory agents. Among them, 2-[4-(2-pyridylamino)phenyl]propionic acid (14b) showed excellent antiinflammatory and analgesic activities with less tendency to cause gastric side effects. Structure-activity relationships are discussed.

Tertiary aminoacids

New α-(cyclic tert. aminophenyl)-aliphatic acids, e.g. those of the formula STR1 AND FUNCTIONAL DERIVATIVES THEREOF, ARE ANTI-INFLAMMATORY AGENTS.